8-K: Real Good Food Company Granted Nasdaq Extension to Regain Compliance

Sentiment:

8-K Filing


The Real Good Food Company has been granted an extension by Nasdaq to regain compliance with listing rules, with specific milestones to be met by March 28, 2025.

Delay expectedThe company has experienced delays in filing its periodic financial reports with the SEC.
Worse than expectedThe company is currently not in compliance with Nasdaq listing rules, indicating worse than expected financial performance and operational issues.

Summary

  • The Real Good Food Company received notice from Nasdaq regarding non-compliance with listing rules related to timely filings, minimum bid price, and market value of publicly held shares.
  • The company requested a hearing with the Nasdaq Hearings Panel and presented a plan to regain compliance.
  • The Panel granted an exception allowing the company until March 28, 2025, to cure all deficiencies, subject to meeting specific interim milestones.
  • Failure to meet the timeline or milestones could result in delisting from Nasdaq.
  • The company is working to remedy the deficiencies but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document highlights significant risks and uncertainties regarding the company's ability to maintain its Nasdaq listing, indicating a negative outlook.

Positives

  • The company has been granted an extension to regain compliance with Nasdaq listing rules.
  • The Nasdaq Hearings Panel has accepted the company's plan to address the listing deficiencies.
  • The company has a clear timeline to work towards compliance.

Negatives

  • The company is currently not in compliance with Nasdaq listing rules.
  • There is no guarantee that the company will be able to meet the required milestones.
  • Failure to meet the milestones will result in delisting from Nasdaq.
  • The company has previously failed to file timely financial reports.

Risks

  • The company may not be able to meet the interim milestones required by Nasdaq.
  • The company may not be able to regain compliance with the listing rules by March 28, 2025.
  • The Nasdaq Hearings Panel could reconsider the extension and delist the company.
  • There is a risk of further delays in filing financial reports and restated financial statements.
  • The company may not receive approval for a reverse stock split at the special meeting of stockholders scheduled for December 2024.
  • There is a risk of discovering additional information regarding errors in previously issued financial statements.

Future Outlook

The company is working to regain compliance with Nasdaq listing rules by March 28, 2025, but there is no guarantee of success. The company must meet specific interim milestones to avoid delisting.

Management Comments

  • The company is diligently working to remedy the Nasdaq listing deficiencies within the Cure Period.
  • The company has attempted to identify forward-looking statements by using words such as anticipate, believe, estimate, expect, intend, may, plan, predict, project, should, will, or would, and similar expressions or the negative of these expressions.

Industry Context

This announcement highlights the challenges faced by companies struggling to maintain compliance with exchange listing requirements, particularly in volatile market conditions. It is not uncommon for companies to receive delisting notices and seek extensions to regain compliance.

Comparison to Industry Standards

  • Many companies listed on Nasdaq face similar challenges in maintaining compliance with listing rules, especially during periods of financial difficulty or market downturns.
  • Companies like Bed Bath & Beyond and Revlon have faced similar delisting threats due to low share prices and financial issues.
  • The requirement to maintain a minimum bid price of $1.00 per share and a minimum market value of $15 million are standard for Nasdaq listings, and companies that fail to meet these criteria are at risk of delisting.

Stakeholder Impact

  • Shareholders face the risk of delisting and potential loss of investment.
  • Employees may experience uncertainty due to the company's financial challenges.
  • Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

  • The company must meet specific interim milestones during the Cure Period.
  • The company must regain compliance with Nasdaq listing rules by March 28, 2025.
  • The company will hold a special meeting of stockholders in December 2024 to approve a reverse stock split.

Key Dates

DateDescription
December 2, 2024Date of the Panel's decision granting the company's request for continued listing.
December 2024Special meeting of stockholders scheduled to approve a reverse stock split.
March 28, 2025Deadline for the company to cure all listing deficiencies.

Keywords

Nasdaq, delisting, compliance, listing rules, minimum bid price, market value, financial reports, extension, milestones

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.